Literature DB >> 22426973

Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis.

John G F Cleland1, Valentina Carubelli, Teresa Castiello, Ashraf Yassin, Pierpaolo Pellicori, Renjith Antony.   

Abstract

Most patients with heart failure have mild or moderate renal dysfunction. This reflects the combined impact of chronic renal parenchymal disease, renal artery disease, renal congestion and hypoperfusion, neuroendocrine and cytokine activation and the effects of treatments for heart failure. Remarkably, with good treatment, the average annual rate of decline in renal function is similar in patients with chronic heart failure and healthy people of a similar age. Urea appears to be a stronger marker of an adverse prognosis than creatinine-based measures of renal function. Recent evidence suggests that minor, transient increases in creatinine in the setting of acute heart failure are not prognostically important but persistent deterioration does indicate a higher mortality. The poor prognosis of patients with worsening renal function ensures that few require renal dialysis but this may change as methods to prevent sudden death improve and new ways are found to control fluid congestion. Reversing renal dysfunction and stopping its progression remain important targets for treatment of heart failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426973     DOI: 10.1007/s10741-012-9306-2

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  114 in total

1.  Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure.

Authors:  Robb D Kociol; Melissa A Greiner; Bradley G Hammill; Hemant Phatak; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Authors:  Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

3.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

Review 4.  Heart failure, renal function, and angiotensin converting enzyme inhibitors.

Authors:  J G Cleland; H J Dargie
Journal:  Kidney Int Suppl       Date:  1987-05       Impact factor: 10.545

5.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

6.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

Authors:  Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

7.  Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis.

Authors:  Mehmet Birhan Yilmaz; Etienne Gayat; Reda Salem; Johan Lassus; Maria Nikolaou; Said Laribi; John Parissis; Ferenc Follath; W Franck Peacock; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2011-11       Impact factor: 15.534

8.  Relation of blood urea nitrogen to long-term mortality in patients with heart failure.

Authors:  Clay A Cauthen; Michael J Lipinski; Antonio Abbate; Darryn Appleton; Annunziata Nusca; Amit Varma; Evelyne Goudreau; Michael J Cowley; George W Vetrovec
Journal:  Am J Cardiol       Date:  2008-04-09       Impact factor: 2.778

9.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

Authors:  J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

10.  A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).

Authors:  John G F Cleland; Kevin Goode; Leif Erhardt; Willem J Remme; Andrew Charlesworth; Philip A Poole-Wilson; Andrea Di Lenarda; Peter Hanrath; Michel Komajda; Marco Metra; Karl Swedberg; Christian Torp-Pedersen
Journal:  Cardiovasc Drugs Ther       Date:  2004-03       Impact factor: 3.727

View more
  29 in total

Review 1.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

Review 2.  Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Authors:  Roland E Schmieder; Veselin Mitrovic; Christian Hengstenberg
Journal:  Clin Res Cardiol       Date:  2015-03-19       Impact factor: 5.460

3.  One-year survival and renal function recovery of acute kidney injury patients with chronic heart failure.

Authors:  Wen Zhang; Dan Wen; Yan-Fang Zou; Ping-Yan Shen; Yao-Wen Xu; Hao Shi; Jing Xu; Xiao-Nong Chen; Nan Chen
Journal:  Cardiorenal Med       Date:  2014-12-24       Impact factor: 2.041

4.  Fluid Management in Patients with Chronic Heart Failure.

Authors:  Pierpaolo Pellicori; Kuldeep Kaur; Andrew L Clark
Journal:  Card Fail Rev       Date:  2015-10

5.  Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.

Authors:  Surya P Ayalasomayajula; Thomas H Langenickel; Pierre Jordaan; Wei Zhou; Priyamvada Chandra; Diego Albrecht; Parasar Pal; Iris Rajman; Gangadhar Sunkara
Journal:  Eur J Clin Pharmacol       Date:  2016-05-26       Impact factor: 2.953

6.  Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Matteo Beltrami; Ranuccio Nuti; John G Cleland
Journal:  Clin Res Cardiol       Date:  2018-03-12       Impact factor: 5.460

7.  Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.

Authors:  Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Sreedevi Boggarapu; Gangadhar Sunkara
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

8.  Non-contrast cardiac resynchronization therapy implantation is feasible in case of renal insufficiency.

Authors:  Sok-Sithikun Bun; Decebal Gabriel Latcu; Abdelkarim Errahmouni; Nadir Saoudi
Journal:  J Interv Card Electrophysiol       Date:  2015-06-17       Impact factor: 1.900

Review 9.  Epidemiology and importance of renal dysfunction in heart failure patients.

Authors:  Gregory Giamouzis; Andreas P Kalogeropoulos; Javed Butler; Georgios Karayannis; Vasiliki V Georgiopoulou; John Skoularigis; Filippos Triposkiadis
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 10.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.